Source: WSJ

Category: Digital Media, M&A, R&D, Science

Please use the comments to demonstrate your own ignorance, unfamiliarity with empirical data and lack of respect for scientific knowledge. Be sure to create straw men and argue against things I have neither said nor implied. If you could repeat previously discredited memes or steer the conversation into irrelevant, off topic discussions, it would be appreciated. Lastly, kindly forgo all civility in your discourse . . . you are, after all, anonymous.

2 Responses to “Deal Flurry Shows Drug Makers’ Swing Toward Specialization”

  1. stonedwino says:

    Exactly the mergers we don’t need, like Big Pharma and Cable…who benefits? The insiders…there’s absolutely zero benefit to investors or consumers. Zilch…Pure Corporatism.

  2. supercorm says:

    I don’t understand LLY buying animal health here while everyone divest to focus on core and biologics.

    At the end, most deals in Pharma lately involve a company based in a tax heaven, so saving on taxes is why most deals are accretive. At the end, the US lose another companies paying taxes, and taxpayers have to pay more … again.